

The Dilemma of Medical Marijuana Use by Rheumatology Patients

MARY-ANN FITZCHARLES,¹ DANIEL J. CLAUW,² PETER A. STE-MARIE,¹ AND YORAM SHIR¹

Introduction

“Severe pain” is the most common reason for medicinal herbal cannabis use, with arthritis and musculoskeletal pain cited as the most prevalent specific medical condition (1,2). Eighty percent of marijuana users in a US pain clinic report use for myofascial pain, whereas up to one-third of persons in population studies in the UK and Australia reported use for treatment of arthritis pain (1–3). Similarly, “severe arthritis” is the diagnosis for 65% of Canadians authorized to possess cannabis for medicinal purposes as of June 2013 (4). Medical marijuana has, however, never been recommended by any rheumatology group worldwide for symptom relief in rheumatic conditions. As the health care professionals best placed to advise on issues of rheumatic diseases, rheumatologists must have a voice in the current debate concerning medical marijuana, hereafter identified as herbal cannabis.

Advocacy for access to cannabinoid treatments has led to a societal groundswell, with regulatory bodies around the globe considering the legalization of herbal cannabis for medicinal use. Currently, herbal cannabis is legalized for medicinal use in 20 states in the US as well as in the District of Columbia. Physicians will therefore be caring for patients who may be self-medicating with herbal cannabis or may request medical advice about cannabis. In order to responsibly advise patients on any medical issue, and in particular herbal cannabis, it is essential that the health care professional has a competent knowledge of the

subject based on sound scientific study. In this review, we examined the current evidence for dosing and administration, efficacy, and risks of herbal cannabis in rheumatic pain management, and thereby addressed practical issues confronting rheumatologists whose patients request advice. We confined our comments to herbal cannabis as it pertains to rheumatic conditions, acknowledging that evidence and information may differ for other conditions. We did not enter into the debate addressing the legalization of recreational herbal cannabis.

Herbal cannabis

Prior to present day pharmacology, healers and patients sought relief from pain and suffering by using natural products. The plant *Cannabis sativa*, commonly known as marijuana, has been used for pain relief for millennia, with additional effects on appetite, sleep, and mood, but with psychoactive properties leading to recreational use (5). The analgesic effects of herbal cannabis, derived from the dried leaves and flowers, have been most studied in neuropathic pain conditions.

C sativa contains more than 450 compounds, with at least 70 classified as phytocannabinoids, two of which have particular medical interest (6). The acid precursor of Δ^9 -tetrahydrocannabinol (Δ^9 -THC), transformed by heat into THC, has psychoactive and pain-relieving properties. The second molecule is cannabidiol, with lesser affinity for the cannabinoid receptors and the potential to counteract the negative effects of THC on memory, mood, and cognition. Cannabinoid molecules interact with at least two receptors of the human endocannabinoid system to induce physiologic effects (7,8).

Herbal cannabis may be ingested or inhaled, with the latter route preferred by users due to onset of action within a few minutes. Smoking of cannabis is, however, not medically recommended due to the potential respiratory tract dangers of noxious compounds such as polycyclic aromatic hydrocarbons, tar, and carbon monoxide. Furthermore, plasma concentrations of THC achieved by smoking a “joint,” containing between 0.5 and 1.0 gm of dried substance, are extremely variable, with blood levels varying between 7 and 100 ng/ml. Finally, blood levels are influenced by the plant concentration of THC, variable THC delivered in the smoke, and characteristics of the

¹Mary-Ann Fitzcharles, MBChB, Peter A. Ste-Marie, LLB, Yoram Shir, MD: McGill University Health Centre, Montreal, Quebec, Canada; ²Daniel J. Clauw, MD: University of Michigan Medical Center, Ann Arbor.

Dr. Fitzcharles has received consulting fees, speaking fees, and/or honoraria (less than \$10,000 each) from Abbott, Amgen, Lilly, Pfizer, Purdue, and Valeant. Dr. Clauw has received consulting fees, speaking fees, and/or honoraria (less than \$10,000 each) and/or research grants from Cerephex, Forest, Johnson & Johnson, Lilly, Merck, Nuvo, Pfizer, Purdue, Theravance, and Tonix.

Address correspondence to Mary-Ann Fitzcharles, MBChB, Montreal General Hospital, 1650 Cedar Avenue, Montreal, Quebec, Canada, H3G 1A4. E-mail: mary-ann.fitzcharles@muhc.mcgill.ca.

Submitted for publication September 26, 2013; accepted in revised form December 3, 2013.

Significance & Innovations

- Legitimate use should be reserved only for patients with pain refractory to standard pharmacologic and nonpharmacologic therapies.
- Herbal cannabis should not be smoked.
- The risk/benefit profile of herbal cannabis is inferior to all other analgesic classes other than opioids.
- Persons ages <25 years should be strongly discouraged from any use of herbal cannabis.

smoking method (frequency of inhalation, hold time, and inhalation volume) (9,10). There is also discordance between the measured THC plasma peak and the maximum subjective psychoactive effects that occur an hour later, and can be augmented by opioids. Oral administration results in a more delayed effect, lower peak plasma levels, more protracted pharmacologic effects, and less abuse-related psychoactive effects (11). However, gastrointestinal absorption is more erratic and much of the ingested cannabinoid is eliminated by first-pass metabolism in the liver (11).

The mean concentration of THC in illicit marijuana has almost doubled worldwide in the past decade (12). With THC content of the plant material varying between 1% and 30%, and the bioavailability varying between 2% and 56%, there is no reasonable method to estimate dosing of the herbal compound (13). Since acquisition of herbal cannabis for medical reasons is mostly via the illegal route, even where medical use is legalized, these higher concentrations of THC might lead to increased physical and psychomotor effects. Therefore, the lack of the most elementary requirements for responsible drug administration must call into question any use of herbal cannabis for rheumatic pain treatment at this time.

Pain management of patients with rheumatic pain

As arthritis pain contributes to poor patient global well-being, pain relief is an important outcome goal, but unfortunately, pain treatments remain suboptimal in most patients (14). The overriding principle for any pain treatment is to maintain function without sacrificing cognitive or psychomotor function, a concept clearly different from pain management for medical conditions predominantly requiring palliation.

Chronic rheumatic pain remains a challenge, since pain mechanisms are complex dynamic interactions of molecules and nerve pathways subject to nervous system plasticity. Available drugs generally offer a modest effect only, and pain co-associates with sleep disturbance and mood disorders. As treatment success is considered a 30% reduction in pain, and because most pain-relieving medications are associated with considerable side effects, the compliance with prescribed treatments is often poor. It is therefore understandable that patients will continue to seek other remedies to reduce symptoms. Patients with

rheumatic disease commonly use complementary and alternative medicine, and with increasing advocacy for legalization of herbal cannabis as a recreational drug, cannabis may be perceived as a safe treatment option.

Evidence for herbal cannabis in rheumatic conditions

To date, there is no formal study examining the efficacy or adverse effects of herbal cannabis in rheumatic diseases (15). Since our previous review, there has been only a single additional study reporting poorer function and psychological health in fibromyalgia patients using cannabinoids (16). While there is good evidence for efficacy of cannabinoids for treating some chronic pain conditions, such as cancer and neuropathic pain, these pain types have a different underlying mechanism from the mostly peripheral/nociceptive pain in rheumatic diseases (17). Therefore, one cannot extrapolate efficacy to patients with rheumatic conditions.

Information about the effects of cannabinoids in rheumatic diseases is currently derived from anecdotal reports, two small epidemiologic studies, a single study of the oromucosal spray of nabiximols, a combination of Δ^9 -THC and cannabidiol, in patients with rheumatoid arthritis, and two studies of nabilone, a synthetic analog of THC, in fibromyalgia (1,2,18–20). The two population studies from the UK and Australia, with prevalent use for musculoskeletal symptoms, raise a number of concerns: diagnosis and outcome were by patient self-report, patients self-medicated without knowledge of dosing or concomitant treatments, and one-third of the users reported recreational use (1,2). Conclusions based on these studies are therefore questionable. In contrast, when the nabiximol was examined in a randomized clinical trial of 58 patients with rheumatoid arthritis over a 5-week period, there was improvement in pain and quality of sleep (20). The nabilone studies in fibromyalgia patients showed improved pain in one, and noninferiority to amitriptyline for the effect on sleep for the other (18,19). However, the reported effects of these agents, which indeed belong to the class of cannabinoids, cannot necessarily be applied to herbal cannabis, which is a different substance, as described above.

It therefore follows that critical evaluation of safety issues that pertain to both short-term and long-term effects of herbal cannabis also have never been formally reported in persons with classic rheumatic diseases. There is also no sound information regarding the recommended dosing of herbal cannabis, other than patient report. Therefore, the available evidence for efficacy of medical herbal cannabis represents the least convincing form of scientific evidence.

Evidence for risks

Contrary to public belief, inhaled herbal cannabis is not innocuous. Risks can be categorized as the immediate effects on cognition, psychomotor function, cardiovascular effects, and mood, and the chronic consequences on mental ability, pulmonary function, potential cancer risk, and drug dependence. Information on risks of herbal can-

nabis is also mostly derived from reports of recreational users, who are usually younger and in better health than those with a chronic disease. Additionally, the interaction of herbal cannabis with other medications that are being used therapeutically is mostly unknown.

Acute risks

The acute dose-related effects on cognition and psychomotor function are the most well-known immediate consequences of herbal cannabis use, with implications for patient safety. Following administration of inhaled cannabis in varying THC concentrations, regular cannabis users showed impairment in reaction time, selective attention, short-term memory, and motor control for up to 5 hours following consumption, with increasing effects for increasing doses (21). Similarly, the memory-impairing effects of acute cannabis use, possibly specifically attributable to THC, should be kept in mind. These acute effects have implications for medicinal use for two reasons: THC content in street cannabis is increasing and chronic pain management requires continued treatment.

Adverse acute effects on psychomotor function are particularly relevant when subjects drive motorized vehicles. Arthritis per se is seldom a contraindication to drive, and driving in the developed world is an important contribution to independence and quality of life. Acute cannabis use is increasingly appreciated as an accident risk for drivers. In a systematic review and meta-analysis of 9 studies, with inclusion of 49,000 participants, acute cannabis use was associated with at least twice the risk of serious and fatal motor vehicle collisions (22). Indeed, cannabis was also the most prevailing illicit drug identified in 0.5–7.6% of seriously injured drivers from 6 European countries (23). Although alcohol remains the most common substance identified in injured drivers, cannabis was ranked second, with the risk increased when combined with alcohol. Health Canada warns that the ability to drive or perform activities requiring alertness or coordination may be impaired for up to 24 hours following a single consumption (24). Therefore, driving with the concomitant use of herbal cannabis is both a personal and a societal safety risk, which may be further compounded in the presence of other medications. At the very least, medical practitioners must now advise patients that herbal cannabis may impair motor coordination, particularly when driving. However, advising patients not to drive is a recommendation counterintuitive to maintaining normal function.

A less appreciated effect of acute cannabis is noted for the cardiovascular system. Tachycardia and hypotension could compromise cardiovascular status in those with underlying heart disease and be a risk for cardiovascular events (25). Cannabis increases the risk of myocardial infarction 5-fold and reduces the exercise capacity of those with angina pectoris by half (26,27). Lastly, immediate psychiatric effects are increasingly associated with acute cannabis use, including anxiety, agitation, suicidal ideation, and acute psychosis (28).

Chronic risks

The long-term risks of herbal cannabis use in patients with rheumatic disease are unknown. Risks generic to all persons using herbal cannabis include effects on psychological health and association with mental illness, development of dependence and addiction, effects on memory, and cognition and respiratory health (28). Aggravation of depression- and smoking-associated risks may be particularly important for rheumatology patients. These issues seem to be particularly problematic in younger individuals, where we appreciate that many neuroactive drugs may have additional or more pronounced side effects (29). For example, just as suicidality with selective serotonin reuptake inhibitors seems more pronounced in individuals ages <25 years, there is a similar age predisposition for the increased risk of psychosis in young cannabis users.

Although the long-term effect on mood and especially depression still remains unclear, depression is more prevalent in current cannabis users (30). In a US study of more than 8,000 adults, those with cannabis use in the past year had 1.4 times higher odds of current depression than nonusers (30). Aggravation or unmasking of serious psychiatric disease also occurs with herbal cannabis use. Although previously disputed, cannabis is now generally accepted as an agent with addictive potential, especially in a context of an adverse psychosocial setting. Over a 3-year period, the cumulative incidence of cannabis dependence was 37.2% (95% confidence interval [95% CI] 30.7–43.8%) for young recreational users (31).

While cigarette smoking-associated risks for arthritis patients cannot immediately be attributed to the smoking of herbal cannabis, the potential for these adverse effects exists. Apart from the consequences of inhalation of an irritant on respiratory mucosa with development of chronic respiratory disease, there is increasing evidence that herbal cannabis may independently increase risk of lung cancer (32–34). When Swedish military conscripts ages 18–20 years were tracked over a 40-year period, those who had smoked cannabis on at least 50 occasions had a 2-fold risk (hazard ratio 2.12, 95% CI 1.08–4.14) of developing lung cancer, even after adjustments for other risks for lung cancer (34). Although it is recommended that herbal cannabis not be smoked, this remains the most common route of administration for most persons.

Finally, the true motive for use of herbal cannabis, even in persons with an identifiable medical condition, requires careful scrutiny. Often, persons using marijuana for medical reasons have previously been recreational users, raising the possibility of misusing a medical diagnosis to justify use primarily for nonmedical reasons (1,2,35).

Understanding the dilemma for the health care professional

Responsible medical practice requires a physician to provide empathetic and judicious patient care without harm. In light of the current lack of concrete medical evidence for either the efficacy or risks of herbal cannabis for the management of rheumatic symptoms, physicians are obligated to caution patients about the known risks of herbal cannabis that have been reported for recreational users. Simply

acceding to patient demands for a treatment on the basis of popular advocacy, without comprehensive knowledge of an agent, does not adhere to the ethical standards of medical practice. It is understandable that this lack of current scientific evidence must translate into physician insecurity and even distress when attempting to provide rational advice to a patient. Furthermore, any recommended therapy requires proof of concept by sound scientific study that attests to both efficacy and safety. Therefore, before physicians can provide medical recommendation or support for use of herbal cannabis, the minimal standards for pharmacotherapy must be met. At present, these elementary criteria are not fulfilled. In the absence of knowledge of effective dosing or true benefits for herbal cannabis for rheumatic symptoms, the risks extrapolated from study of persons with recreational use seem to tip the balance against use. Therefore, we believe that herbal cannabis should not at this time be allowed exceptional status as a therapy, different from other modes of therapy.

The question arises, then, whether physicians have any basis on which to provide responsible advice to patients beyond the known risk of serious adverse effects. In many jurisdictions, legislation is forcing physicians to accept medical responsibility for their patients who may be using herbal cannabis. For example, in Canada, physicians will be required to provide a document equivalent to a prescription stipulating dosing, frequency, and duration of use (24,36). An additional challenge is presented by the ambiguous terminology used by the courts whereby legal access to herbal cannabis is deemed a Charter Right when a "medical need" has been demonstrated by the patient. If physicians are to "prescribe" medical cannabis for their patients, medical ethics and deontology require physician competence with the prescribed treatment. It is also increasingly recognized that sanctioning use of herbal cannabis for therapeutic reasons is currently provided by small numbers of physicians for the majority of patients (35). In the state of Colorado, almost half of the recommendations had been made by only 15 physicians. Motives for this medical behavior should be questioned and raise ethical concerns.

It is therefore not surprising that recent surveys report that physicians lack confidence in their knowledge of cannabinoids and in their competence to effectively advise patients on the use of medicinal cannabinoids (35). In a survey of family physicians in Colorado, only 19% thought that physicians should recommend medical marijuana, with 92% reporting the need for more education (35). Similarly, two-thirds of Canadian rheumatologists recently surveyed expressed poor confidence in their knowledge of cannabinoid medical use, with 70% stating that there is currently no role for herbal cannabis in the treatment of rheumatic symptoms (37). Even in the setting of some reasonable knowledge of cannabinoid molecules and the endocannabinoid system, the absence of evidence for clinical use of herbal cannabis in rheumatic conditions must be discomfiting for any health care professional or rheumatologist intending to provide an herbal cannabis treatment recommendation. Additional knowledge of these molecules is required, but knowledge alone will not fill the void due to absence of clinical study. This evident

mismatch between dictates from regulatory bodies, patient advocacy, and prudent clinical care is troubling; irresponsible requirements by regulatory authorities might compromise patient and society well-being. In light of other available treatment options for the management of arthritis pain, lack of sound evidence for effect, and potential for harm, herbal cannabis cannot be recommended for arthritis pain management at this time.

Conclusion

There is an ever-increasing hiatus between public advocacy for herbal cannabis as a therapeutic agent in rheumatic conditions and the medical evidence for efficacy and side effects. This serious shortfall covers many aspects of herbal cannabis as a therapeutic agent, including uncertainty of compound content, unknown dosing, recommendations not to use by inhalation, and the indicators of harm, both in the acute as well as chronic setting. Taking all factors into consideration, health care professionals should currently dissuade rheumatology patients from using herbal cannabis as a therapy. The evident mismatch between patients' needs and good medical practice may in part be politically driven, with regulatory bodies acceding to public pressure. Rheumatologists should advocate for further study of individual cannabinoid molecules whereby dosing can be accurately controlled and efficacy and safety can be assessed using a standard scientific method.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published.

REFERENCES

1. Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. *Harm Reduct J* 2005;2:18.
2. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. *Int J Clin Pract* 2005;59:291–5.
3. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. *J Opioid Manag* 2009;5:257–86.
4. Office of the Information Commissioner of Canada. Information request (ATI 2013-00282) under the Access to Information Act. 2013.
5. Kalant H. Medicinal use of cannabis: history and current status. *Pain Res Manag* 2001;6:80–91.
6. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. *Life Sci* 2005;78:539–48.
7. Pertwee RG. Cannabinoid pharmacology: the first 66 years. *Br J Pharmacol* 2006;147 Suppl:S163–71.
8. Pertwee RG. Cannabinoid receptors and pain. *Prog Neurobiol* 2001;63:569–611.
9. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ* 2010;182:E694–701.
10. Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. *Drug Alcohol Depend* 2009;103:107–13.
11. Huestis MA. Human cannabinoid pharmacokinetics. *Chem Biodivers* 2007;4:1770–804.

12. Cascini F, Aiello C, Di Tanna G. Increasing Δ -9-tetrahydrocannabinol (Δ -9-THC) content in herbal cannabis over time: systematic review and meta-analysis. *Curr Drug Abuse Rev* 2012;5:32–40.
13. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, Δ 9-tetrahydrocannabinol, cannabidiol and cannabinol. *Handb Exp Pharmacol* 2005;168:657–90.
14. Goldenberg DL, Clauw DJ, Fitzcharles MA. New concepts in pain research and pain management of the rheumatic diseases. *Semin Arthritis Rheum* 2011;41:319–34.
15. Fitzcharles MA, McDougall J, Ste-Marie PA, Padjen I. Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm? [review]. *Arthritis Rheum* 2012;64:2417–25.
16. Ste-Marie PA, Fitzcharles MA, Gamsa A, Ware MA, Shir Y. Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. *Arthritis Care Res (Hoboken)* 2012;64:1202–8.
17. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: a systematic review of randomized trials. *Br J Clin Pharmacol* 2011;72:735–44.
18. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. *Anesth Analg* 2010;110:604–10.
19. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. *J Pain* 2008;9:164–73.
20. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology (Oxford)* 2006;45:50–2.
21. Mensinga TT, de Vries I, Kruidenier M, Hunault CC, van den Hengel-Koot IS, Fijen JW, et al. A double-blind, randomized, placebo-controlled, cross-over study on the pharmacokinetics and effects of cannabis. 2006. URL: <http://rivm.openrepository.com/rivm/bitstream/10029/7272/2/267002002.pdf.txt>.
22. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. *BMJ* 2012;344:e536.
23. Legrand SA, Isalberti C, der Linden TV, Bernhoft IM, Hels T, Simonsen KW, et al. Alcohol and drugs in seriously injured drivers in six European countries. *Drug Test Anal* 2013;5:156–65.
24. Canada Department of Justice, Acts, Regulations, and Health. Marijuana medical access regulations. 2001. URL: <http://laws-lois.justice.gc.ca/eng/regulations/sor-2001-227/FullText.html>.
25. Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? *Int J Cardiol* 2007;118:141–4.
26. Aronow WS, Cassidy J. Effect of marijuana and placebo-marijuana smoking on angina pectoris. *N Engl J Med* 1974;291:65–7.
27. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. *Circulation* 2001;103:2805–9.
28. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. *Prog Neuropsychopharmacol Biol Psychiatry* 2004;28:849–63.
29. Fernandez-Espejo E, Viveros MP, Nunez L, Ellenbroek BA, Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. *Psychopharmacology* 2009;206:531–49.
30. Harder VS, Morral AR, Arkes J. Marijuana use and depression among adults: testing for causal associations. *Addiction* 2006;101:1463–72.
31. Van der Pol P, Liebrechts N, de Graaf R, Korff DJ, van den Brink W, van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. *Drug Alcohol Depend* 2013;133:352–9.
32. Taylor DR, Hall W. Respiratory health effects of cannabis: position statement of the Thoracic Society of Australia and New Zealand. *Intern Med J* 2003;33:310–3.
33. Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, et al. Cannabis use and risk of lung cancer: a case-control study. *Eur Respir J* 2008;31:280–6.
34. Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. *Cancer Causes Control* 2013;24:1811–20.
35. Kondrad E, Reid A. Colorado family physicians' attitudes toward medical marijuana. *J Am Board Fam Med* 2013;26:52–60.
36. Fletcher J. Marijuana is not a prescription medicine [editorial]. *CMAJ* 2013;185:369.
37. Fitzcharles M, Ste-Marie PA, Clauw DJ, Jamal S, Karsh J, LeClercq S, et al. Rheumatologists lack confidence in knowledge of cannabinoids in the management of rheumatic conditions: a needs assessment of Canadian rheumatologists [abstract]. *Arthritis Rheum* 2013;65 Suppl:S49.